Newcastle Disease, Infectious Bronchitis, Avian Influenza (H9 Subtype), Fowl Adenovirus and Infectious Bursal Disease Vaccine, Inactivated
- Indication / Application:Prevention of Newcastle Disease(sub-genotype VII), Infectious Bronchitis virus strain QX，Avian Influenza (H9N2 subtype clade 4.1.a and 4.1.b),Fowl Adenovirus and Infectious Bursal Disease Virus.
- Manufacturing: Produced in GMP-certified facility
- Supply Mode: Bulk Supply / Distributor / OEM Available
- Origin: China
Generic Name
Newcastle Disease, Infectious Bronchitis, Avian Influenza (H9 Subtype), Fowl Adenovirus and Infectious Bursal Disease Vaccine, Inactivated
Composition and Content
| Disease | Strain/Serotype | Antigen Content | Optional Strain(s) |
|---|---|---|---|
| ND | La Sota | ≥ 108.5 EID50/0.1ml | La Sota + A-VII |
| IB | M41 | ≥ 106.5 EID50/0.1ml | QX; M41 + QX |
| AI(H9N2) | Clade 9.4.2.5 | ≥ 108.5 EID50/0.1ml | H9 (9.4.1a); H9 (9.4.1b) |
| FAdV | FAdV-4 | ≥ 107.0 TCID50/dose | FAdV-2/FAdV-3/FAdV-5/FAdV-8a |
| FAdV-8b | ≥ 107.0 TCID50/dose | ||
| FAdV-11 | ≥ 107.0 TCID50/dose | ||
| IBD | B87 + rVP2 | B87 ≥ 106.5 TCID50/dose |
CA; CF (W252); rVP2 (cIBDV; varIBDV; vvIBDV; nVarIBDV) |
| rVP2: AGP ≥ 1:8/dose |
Indications
For the prevention of Newcastle disease (La Sota strain), infectious bronchitis (M41 strain), avian influenza (H9N2 subtype, clade 9.4.2.5), fowl adenovirus infection (serotypes 4, 8b, and 11), and infectious bursal disease. Immunity develops 14-21 days after vaccination and lasts for 3 months.
Dosage and Administration
Administer subcutaneously in the neck or intramuscularly.
Chickens 1-4 weeks of age: 0.3 mL per bird; chickens over 4 weeks of age: 0.5 mL per bird.
Adverse Reactions
Generally, no adverse reactions occur.
Specification
250 mL/bottle; 500 mL/bottle.
Storage and Shelf Life
Store at 2-8°C. Shelf life: 24 months.
Appearance
A uniform milky-white emulsion.
Precautions
- 1. Vaccinate healthy chickens only. Do not use in emaciated or sick chickens.
- 2. Before use, check for a damaged vial, missing label, foreign matter, or severe oil-water separation. Do not use if any abnormality is found.
- 3. Allow the vaccine to reach room temperature and shake thoroughly before use.
- 4. Use within 2 hours after first opening and prevent contamination.
- 5. This vaccine may be used with live Newcastle disease and infectious bronchitis vaccines to enhance cellular and mucosal immunity.
Features
- After a decade of R&D, WollVac’s latest product makes its grand launch in 2025. Offering "one injection for five protections," it enhances epidemic prevention efficiency and effectiveness.
- Featuring carefully selected strains and viral composite subunit antigens, this innovative solution is a pioneering breakthrough in China. Formulated with a composite adjuvant, it leverages the advantages of compound vegetable oil to ensure zero stress on animals.
The use of complex antigens:
Serotype matching is essential for effective vaccine protection. Using real-time data from the Shandong Provincial Engineering Laboratory for Animal Pathogenic Microorganisms Testing Center, the R&D Center evaluates prevalent strains from the epidemic pathogen bank through multiple stages—preliminary lab screening, animal testing, and cross-protective antibody assessment. The selected dominant strains ensure broad and high-efficacy protection.
| Antigen | ND | IB | AI H9N2 | FADV | IBDV |
|---|---|---|---|---|---|
| Strain | VII type | QX |
h 9.4.1.a + h 9.4.1.b h 9.4.2.5b + h 9.4.2.5c |
C4 + E8b + D11 | cvvIBDV + nvIBDV |